zb002
Generic: anti-TNFα monoclonal antibody
zb002: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Zenas BioPharma, Inc. (ZBIO) | Phase 1 |
Clinical Trials (1)
A Phase 1, 2-Part, Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB002 in Healthy Volunteers (HVs) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety and PK of ZB002 in Participants With Rheumatoid Arthritis (RA)
Frequently asked questions
Who is developing zb002?
zb002 is being developed by Zenas BioPharma, Inc..
How many clinical trials involve zb002?
BioSniper tracks 1 clinical trial involving zb002.
Get deeper analysis on zb002
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis